Ernexa Therapeutics reports Q3 operating loss $2M vs $2.3M last year

“We continue to operate with financial discipline, focusing our resources on advancing our cell therapy programs toward the clinical stage,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics (ERNA). “This approach gives us the flexibility to pursue strategic collaborations and progress our lead programs, including ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease. We are well-positioned to advance our clinical and regulatory strategies toward our first-in-human study next year.”